Neuroblastomas are the most common cancer in infants, with about 700–800 diagnoses per year in the US, according to the American Cancer Society. Some of the most high-risk cases are driven by elevated ...

Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed a phase 3 trial in lymphoma – but the company won't be taking the drug forward itself. Enter ...

About NRX-0305 NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating ...

Shares of Puma Biotechnology PBYI have rallied 35.3% in the past six months against the industry’s decline of 9.2%. The ...

Cell cycle events are controlled tightly by several kinase families including CDKs, Plks, and Aurora kinases. What is interesting about these kinases is that they don't always act alone.

By highlighting two examples of kinase signaling (Aurora kinases and phosphatidylinositol-3-OH kinases) in which such readouts are inconsistent, we argue that the phenotypes need not necessarily ...

orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024 ...